Dongsung Pharmaceutical Co., Ltd.

As of June 30, 2026, Dongsung Pharmaceutical Co., Ltd. has 96.62M shares outstanding.

As of June 30, 2026, Dongsung Pharmaceutical Co., Ltd. maintains a current ratio of 1.24, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 44.13, indicating elevated leverage, while an interest coverage ratio of -1.21 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Dongsung Pharmaceutical Co., Ltd. posted a negative return on equity (ROE) of -18.00, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.49, reflecting losses generated across the asset base. The company generates approximately 260.34M in revenue per employee across its workforce of 315.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.33 indicates how many times Dongsung Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Dongsung Pharmaceutical Co., Ltd. recorded an income tax benefit of -5.99B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -17.51B and -11.52B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Dongsung Pharmaceutical Co., Ltd.'s stock has gained approximately 32.48% over the past 52 weeks. The 50-day moving average sits at 1,399.12, while the 200-day moving average is 2,816.42.

Over the twelve months ended June 30, 2026, Dongsung Pharmaceutical Co., Ltd. generated 82.07B in revenue and converted that into -11.52B in net income, yielding earnings per share of -275.48. EBITDA reached -6.42B, while operating income came in at -8.45B.

As of June 30, 2026, Dongsung Pharmaceutical Co., Ltd. holds 37.47B in cash and equivalents against 38.61B in total debt, resulting in a net debt position of 1.11B. Total book value stands at 87.49B, with working capital of 15.48B providing operational flexibility.

Dongsung Pharmaceutical Co., Ltd. produced -25.26B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -952.00M in capital expenditures, free cash flow totaled -26.21B - equivalent to -626.66 per share.

Over the twelve months ended June 30, 2026, Dongsung Pharmaceutical Co., Ltd. posted a gross margin of 42.10, reflecting its pricing power and cost economics. The operating margin of -10.30 and net profit margin of -14.04 provide insight into operational efficiency.

Dongsung Pharmaceutical Co., Ltd.'s most recent stock split took place on January 2, 2009 with a 1:5 split ratio.